Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often
ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Background Exosomes from cancer cells or immune cells, carrying bio-macromolecules or
microRNAs (miRNAs), participate in tumor pathogenesis and progression by modulating …

Objective: The aim of the study was to identify the survival of patients with locally advanced
pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant …

Purpose: Immune checkpoint inhibition has been shown to generate profound and durable
responses in mismatch repair deficient (MMR-D) solid tumors and has elicited interest in …

Pancreatic cancer usually results in poor survival with limited options for treatment, as most
affected individuals present with advanced disease. Early detection of preinvasive …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …